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Mucormycosis is an angioinvasive fungal infection due to fungi 
of the order Mucorales. The prognosis from mucormycosis can 
be poor despite early diagnosis and aggressive therapy. The 
systematic review and meta-analysis by Muthu and colleagues 
[1] investigated the rate of mortality in patients with pulmonary 
mucormycosis. While there had been a significant decrease in 
the mortality rate over time, the recent (2010-2020) rate of 
mortality is still substantial, in which about one in two patients 
(49.8%; 95% confidence interval 43.2% to 56.3%) with 
pulmonary mucormycosis died from the disease. Yet, patients 
originated from the lower-middle-income countries had a 
higher mortality rate, in which about three in four patients 
(71.5%; 95% confidence interval 58.7% to 84.3%) with 
pulmonary mucormycosis died from the disease. Indeed, there 
has been a recent surge in the occurrence of mucormycosis in 
lower-middle-income countries,  especially in India. As raised 
by Szarpak [2], the increased incidence with a fairly severe 
course of mycormycosis was reported in patients with a history 
of coronavirus disease 2019 (COVID-19) and received 
systemic corticosteroid therapy.  
 
The presence of multiple risk factors in patients with COVID-
19, along with the additional immunosuppression caused by 
systemic corticosteroids, predispose the occurrence of 
mucormycosis, which could negate the mortality benefits 
offered by systemic corticosteroids in this patient population 
[3]. Common risk factors include the presence of diabetes 
mellitus, particularly with ketoacidosis. Noteworthily, the 
management of patients with mucormycosis, which is 
considered rare before the COVID-19 pandemic, had not been 
optimal as described in a case report [4]. Optimal antifungal 
therapy is of utmost importance considering the substantial rate 
of mortality.   
 
Intravenous amphotericin B is the drug of choice for initial 
therapy of mucormycosis; a lipid formulation of amphotericin 
B (liposomal amphotericin B or amphotericin B lipid) is 
preferred to reduce the risk of nephrotoxicity. In a meta-
analysis of five randomized trials, the incidence of 
nephrotoxicity was significantly lower with liposomal 
amphotericin B compared with amphotericin B deoxycholate 
(15% versus 33%; relative risk = 0.48; 95% confidence interval 
0.36 to 0.64) [6]. The usual starting dose for amphotericin B is 
5 mg/kg daily, which can be increased up to 10 mg/kg daily to 
control the infection. 
 
While amphotericin B is generally considered the first-line 
agent for the treatment of mucormycosis. Posaconazole or 
isavuconazole is used as step-down therapy for patients who 
have responded to amphotericin B. Therefore, once patients 
respond and are deemed suitable for discharge, they could be 
initiated with either one of the aforementioned antifungal 
agents. Posaconazole and isavuconazole are broad-spectrum 
azoles that are active in vitro against the pathogens of 
mucormycosis. A systematic review [7] of 96 case reports of 
patients with mucormycosis reported a response rate of 72.9% 
with posaconazole. On the other hand, isavuconazole has been 
evaluated in a multicenter open-label single-arm study that 
included a total of 37 patients with mucormycosis [8]. When 
the researchers compared patients, who received isavuconazole 
with their contemporary counterparts who received 
amphotericin B (the majority received a lipid formulation), it 
was observed that the weighted all-cause mortality was similar 




in those who received isavuconazole (33%) and in those who 
received amphotericin B followed by posaconazole (41%). 
Posaconazole (delayed-release tablets) can be dosed at 300 mg 
every 12 hours on the first day, then 300 mg once daily, with 
no dosage adjustment necessary for patients with a decline in 
renal function. Whereas isavuconazole can be loaded at a dose 
of 200 mg every 8 hours for 2 days, followed by a maintenance 
dose of 200 mg orally once daily starting 12 to 24 hours after 
the last loading dose.  
 
Antifungal therapy should be continued until clinical resolution 
of the signs and symptoms, as well as resolution of radiographic 
signs of mucormycosis. Perhaps in the context where there is a 
widespread outbreak of mucormycosis, the use of systemic 
corticosteroids should be more judicious in patients at high risk, 
such as those with diabetes, keeping in mind that systemic 
corticosteroids could aggravate hyperglycemia. The use of 
intravenous pulse methylprednisolone therapy for as short as 
three days to limit its side effects can be considered [9]. 
Besides, baricitinib, a Janus kinase inhibitor, which has proven 
mortality benefits, can be considered as an alternative to 
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